Heska (NASDAQ:HSKA) Rating Lowered to Hold at BidaskClub

Share on StockTwits

BidaskClub cut shares of Heska (NASDAQ:HSKA) from a buy rating to a hold rating in a research note published on Tuesday, August 28th.

A number of other research analysts have also recently commented on HSKA. Zacks Investment Research raised Heska from a sell rating to a hold rating in a report on Thursday, May 3rd. ValuEngine raised Heska from a sell rating to a hold rating in a report on Friday, May 4th. Canaccord Genuity reissued a buy rating and issued a $95.00 price target on shares of Heska in a report on Monday, May 7th. Benchmark boosted their price target on Heska from $90.00 to $100.00 and gave the stock a buy rating in a report on Monday, May 7th. Finally, B. Riley boosted their price target on Heska from $77.00 to $93.00 and gave the stock a neutral rating in a report on Friday, May 18th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of Hold and an average target price of $107.50.

Shares of HSKA stock traded up $2.27 during trading hours on Tuesday, reaching $111.65. 32,140 shares of the company traded hands, compared to its average volume of 32,080. Heska has a 12-month low of $56.59 and a 12-month high of $112.25. The stock has a market cap of $820.03 million, a P/E ratio of 53.94 and a beta of 0.52.

Heska (NASDAQ:HSKA) last posted its quarterly earnings data on Tuesday, August 7th. The medical research company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.07. Heska had a return on equity of 11.49% and a net margin of 4.67%. The firm had revenue of $29.66 million for the quarter, compared to analysts’ expectations of $30.19 million. equities analysts forecast that Heska will post 1.67 earnings per share for the current year.

In other news, EVP Rod Lippincott sold 6,371 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $104.00, for a total transaction of $662,584.00. Following the sale, the executive vice president now directly owns 12,135 shares of the company’s stock, valued at approximately $1,262,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jason A. Napolitano sold 1,200 shares of the company’s stock in a transaction that occurred on Monday, July 9th. The stock was sold at an average price of $110.00, for a total value of $132,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,778 shares of company stock worth $5,282,310. 14.70% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Curbstone Financial Management Corp raised its holdings in shares of Heska by 11.8% during the 2nd quarter. Curbstone Financial Management Corp now owns 5,700 shares of the medical research company’s stock worth $592,000 after acquiring an additional 600 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Heska by 4.2% during the 1st quarter. Rhumbline Advisers now owns 15,399 shares of the medical research company’s stock worth $1,218,000 after acquiring an additional 614 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Heska by 23.0% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 3,581 shares of the medical research company’s stock worth $372,000 after acquiring an additional 670 shares in the last quarter. Swiss National Bank raised its holdings in shares of Heska by 6.6% during the 1st quarter. Swiss National Bank now owns 11,300 shares of the medical research company’s stock worth $893,000 after acquiring an additional 700 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Heska by 17.4% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,400 shares of the medical research company’s stock worth $427,000 after acquiring an additional 800 shares in the last quarter. 89.17% of the stock is currently owned by institutional investors and hedge funds.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Further Reading: Market Capitalization – What it Means for Investors

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.